Abstract

Only a subset of cancer patients respond to T-cell checkpoint inhibitors, highlighting the need for alternative immunotherapeutics. We performed CRISPR-Cas9 screens in a leukemia cell line to identify perturbations that enhance natural killer effector functions. Our screens defined critical components of the tumor-immune synapse and highlighted the importance of cancer cell interferon-g signaling in modulating NK activity. Surprisingly, disrupting the ubiquitin ligase substrate adaptor DCAF15 strongly sensitized cancer cells to NK-mediated clearance. DCAF15 disruption induced an inflamed state in leukemic cells, including increased expression of lymphocyte costimulatory molecules. Proteomic and biochemical analysis revealed that cohesin complex members were endogenous client substrates of DCAF15. Genetic disruption of DCAF15 was phenocopied by treatment with indisulam, an anticancer drug that functions through DCAF15 engagement. In AML patients, reduced DCAF15 expression was associated with improved survival. These findings suggest that DCAF15 inhibition may have useful immunomodulatory properties in the treatment of myeloid neoplasms.

Data availability

Sequencing data have been deposited in GEO under accession code GSE134173.All data generated or analyzed during this study are included in the manuscript and supporting files.Figure 1C: Table S2Figure 2D: Table S3Figure 4F: Table S4Figure 7C: Table S6

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Matthew Pech

    Department of Oncology, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Matthew Pech, employee of Calico Life Sciences, LLC.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1451-0234
  2. Linda E Fong

    Department of Oncology, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Linda E Fong, employee of Calico Life Sciences, LLC.
  3. Jacqueline E Villalta

    Department of Oncology, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Jacqueline E Villalta, employee of Calico Life Sciences, LLC.
  4. Leanne JG Chan

    Department of Proteomics, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Leanne JG Chan, employee of Calico Life Sciences, LLC.
  5. Samir Kharbanda

    Department of Oncology, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Samir Kharbanda, employee of Calico Life Sciences, LLC.
  6. Jonathon J O'Brien

    Department of Proteomics, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Jonathon J O'Brien, employee of Calico Life Sciences, LLC.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9660-4797
  7. Fiona E McAllister

    Department of Proteomics, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Fiona E McAllister, employee of Calico Life Sciences, LLC.
  8. Ari J. Firestone

    Department of Oncology, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Ari J. Firestone, employee of Calico Life Sciences, LLC.
  9. Calvin H Jan

    Department of Research, Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Calvin H Jan, employee of Calico Life Sciences, LLC.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9033-4028
  10. Jeffrey Settleman

    Department of Oncology, Calico Life Sciences LLC, San Diego, United States
    For correspondence
    jsettleman@gmail.com
    Competing interests
    Jeffrey Settleman, employee of Calico Life Sciences, LLC; Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3569-6493

Funding

Calico Life Sciences LLC

  • Matthew Pech
  • Linda E Fong
  • Jacqueline E Villalta
  • Leanne JG Chan
  • Samir Kharbanda
  • Jonathon J O'Brien
  • Fiona E McAllister
  • Ari J. Firestone
  • Calvin H Jan
  • Jeffrey Settleman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Stipan Jonjic, University Rijeka, Croatia

Version history

  1. Received: April 3, 2019
  2. Accepted: August 2, 2019
  3. Accepted Manuscript published: August 27, 2019 (version 1)
  4. Version of Record published: August 28, 2019 (version 2)
  5. Version of Record updated: September 10, 2019 (version 3)

Copyright

© 2019, Pech et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 12,174
    Page views
  • 1,537
    Downloads
  • 49
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matthew Pech
  2. Linda E Fong
  3. Jacqueline E Villalta
  4. Leanne JG Chan
  5. Samir Kharbanda
  6. Jonathon J O'Brien
  7. Fiona E McAllister
  8. Ari J. Firestone
  9. Calvin H Jan
  10. Jeffrey Settleman
(2019)
Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance
eLife 8:e47362.
https://doi.org/10.7554/eLife.47362

Share this article

https://doi.org/10.7554/eLife.47362

Further reading

    1. Cancer Biology
    2. Cell Biology
    Julian J A Hoving, Elizabeth Harford-Wright ... Alison C Lloyd
    Research Article

    Collective cell migration is fundamental for the development of organisms and in the adult, for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell-cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell-cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during rat Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell-cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell-surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective Schwann cell migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased Schwann cell collective migration and increased clustering of Schwann cells within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.

    1. Cancer Biology
    2. Structural Biology and Molecular Biophysics
    Johannes Paladini, Annalena Maier ... Stephan Grzesiek
    Research Article

    Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively. It was recently established that binding of type II ATP site inhibitors, such as imatinib, generates a force from the KD N-lobe onto the SH3 domain and in consequence disassembles the core. Here, we demonstrate that the C-terminal αI-helix exerts an additional force toward the SH2 domain, which correlates both with kinase activity and type II inhibitor-induced disassembly. The αI-helix mutation E528K, which is responsible for the ABL1 malformation syndrome, strongly activates Abl by breaking a salt bridge with the KD C-lobe and thereby increasing the force onto the SH2 domain. In contrast, the allosteric inhibitor asciminib strongly reduces Abl’s activity by fixating the αI-helix and reducing the force onto the SH2 domain. These observations are explained by a simple mechanical model of Abl activation involving forces from the KD N-lobe and the αI-helix onto the KD/SH2SH3 interface.